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Available online 24 July 2010Diffusible oligomeric assemblies of the amyloid β-protein (Aβ) could be the primary factor in
the pathogenic pathway leading to Alzheimer's disease (AD). Converging lines of evidence
support the notion that AD begins with subtle alterations in synaptic efficacy, prior to the
occurrence of extensive neuronal degeneration. Recently, however, a shared or overlapping
pathogenesis for AD and epileptic seizures occurred as aberrant neuronal hyperexcitability,
as well as nonconvulsive seizure activity were found in several different APP transgenic
mouse lines. This generated a renewed attention to the well-known comorbidity of AD and
epilepsy and interest in how Aβ oligomers influence neuronal excitability. In this study
therefore, we investigated the effect of various in vitro-aged Aβ(1–42) oligomer solutions on
the perforant pathway-evoked field potentials in the ventral hippocampal dentate gyrus in
vivo. Firstly, Aβ oligomer solutions (1 μl, 200 μM)whichhadbeen aggregated in vitro for 0, 24 or
72 h were injected into the hippocampus of urethane-anesthetized rats, in parallel with in
vitro physico-chemical characterization of Aβ oligomerization (atomic force microscopy,
thioflavin-T fluorescence). We found a marked increase of hippocampal population spike
(pSpike) after injection of the 24-h Aβ oligomer solution and a decrease of the pSpike
amplitude after injection of the 72-h Aβ oligomer. Since urethane anesthesia affects the
properties of hippocampal evoked potentials, we repeated the injection of these two Aβ
oligomer solutions in awake, freelymoving animals. Evoked responses to perforant pathway
stimulation revealed a 70% increase of pSpike amplitude 50 min after the 24-h Aβ oligomer
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228 B R A I N R E S E A R C H 1 3 5 4 ( 2 0 1 0 ) 2 2 7 – 2 3 5synaptic potentials, were not affected by the Aβ injection. These results demonstrate that
oligomeric Aβ aggregates elicit opposite electrophysiological effects on neuronal excitability
which depend on their degree of oligomerization.
© 2010 Elsevier B.V. All rights reserved.1. Introduction
According to the current view on the molecular pathological
mechanisms of Alzheimer's disease (AD), the accumulation
and aggregation of Aβ initiates a cascade of cellular changes
that gradually leads to memory loss. It is known that amyloid
monomers, produced from the amyloid precursor protein,
form aggregates rich in β-sheet structure in a slow oligomer-
ization process (DeMager et al., 2002; Nandi, 1996; Stine et al.,
2003) and gradually form deposits in the limbic and associa-
tion cortex of the brain of AD patients (Glenner et al., 1984;
Masters et al., 1985). It has been shown in several studies that
the small and soluble, non-fibrillar oligomers, rather than the
large Aβ fibrils, are toxic (Cleary et al., 2005; Dahlgren et al.,
2002; Haass and Selkoe, 2007; Kirkitadze et al., 2002; Klein
et al., 2004; Lacor et al., 2004; McLean et al., 1999; Selkoe, 2002;
Walsh et al., 2002; Walsh and Selkoe, 2004).
Aβ oligomers injected into the brain have been found to
initiate various cytotoxic and immunological reactions, in-
cluding axonal pathway distortion, dendritic arbor shrinkage,
microglia activation, free radical release and inflammatory
reactions (Walsh and Selkoe, 2004). Electrophysiologically it is
well established, that Aβ oligomers decrease synaptic efficacy
(Walsh and Selkoe, 2004, 2007). The smallest synaptotoxic
species to impair synapse structure and function are reported
to be Aβ dimers (Mc Donald et al., 2010; Shankar et al., 2008).
Recently aberrant excitatory neuronal activity and non-
convulsive seizures were found in several different APP
transgenic mouse lines (Minkeviciene et al., 2009; Palop
et al., 2007). This highlighted the well-known clinical fact
that there is a comorbidity of AD and epilepsy (Larner, 2010).
Whether this comorbidity is just epiphenomenal, or there is a
shared pathophysiology of seizures and AD, remains elusive
(Larner, 2010; Minkeviciene et al., 2009).
Indeed there are conflicting data about how Aβ oligomers
influence neuronal excitability. In an earlier whole cell
recording study Aβ selectively augmented NMDA receptor-
mediated synaptic currents (Wu et al., 1995a,b), while later in a
similar in vitro study, oligomeric Aβ decreased neuronal
excitability (Yun et al., 2006). In an in vivo iontophoretic
study, Aβ application irreversibly increased NMDA responses
in the extracellular single-unit recordings (Molnar et al., 2004).
Furthermore, as Aβ has a high affinity for the lipid component
of the membrane (Verdier and Penke, 2004), it can interact
with membrane proteins, including voltage operated calcium
channels. However, the oligomerisation state of Aβ differen-
tially affected the calcium channels (Innocent et al., 2010;
Nimmrich et al., 2008; Ueda et al., 1997).
In this study therefore, to assess the importance of Aβ
oligomerization, we measured the perforant path-evoked
population potentials, to test the electrophysiological effect
of different Aβ(1–42) oligomers on neuronal function. We
injected in vitro-aged Aβ oligomer solutions with differentaggregation times into the ventral hippocampal dentate gyrus
of both anesthetized and awake freely moving rats. We
observed a marked increase of the perforant path-evoked
population action potentials (pSpike) after injection of the
solution with 24 h aggregation time and a decrease of pSpike
amplitude after injection of the 72-h solution. The same
effects were observed in freely moving rats following injection
of the 24-h and 72-h Aβ solutions. Thus, Aβ oligomers have
opposite effects on neuronal excitability which depend on
their degree of oligomerization.2. Results
2.1. Electrophysiological results
In anesthetized rats injectedwith 0-h Aβ(1–42) solution (1 μl of
200 μMAβ), the hippocampal pSpike amplitude was unaltered
(Fig. 1). The injection of 24-h Aβ aggregates increased, while
72-h Aβ aggregates decreased the pSpike amplitude, com-
pared to the ACSF-treated animals at the same post-injection
time (Fig. 1). The maximum effects were 161±13% for the 24 h
aggregates, and 60±8% for the 72-h aggregates, measured
40 min after the end of the 30 min injection (Fig. 1).
In freely moving rats, the effect of the 24-h and 72-h Aβ
aggregates on the hippocampal pSpike amplitude was more
pronounced. These changes in neuronal excitability were
significant as early as 30 min after the end of the Aβ injection
(Fig. 2A). The maximum effect was 170±14% of the control for
the 24-h aggregates, and 45±10% for the 72-h aggregates,
50 min after the end of the Aβ solution injection (Fig. 2B). The
slope of population excitatory postsynaptic potential (pEPSP),
which was analyzed from the same traces, shows no change
following injection of either of the two aggregates (Fig. 2C).
2.2. In vitro characterization and reproducibility of
Aβ solutions
Monomeric Aβ(1–42) was dissolved in artificial cerebro-spinal
fluid (ACSF) to provide a solution suitable for in vivo
administration. Aβ forms aggregates of various size and
morphology even in one particular solution, making the
characterization of the in vivo effects of the individual
aggregate-types difficult. To vary the aggregate composition
of the Aβ solutions we simply incubated the samples for 0, 24
and 72 h at room temperature before administration. To
characterize the size and morphology of Aβ aggregates, the
samples were investigated by atomic force microscopy (AFM).
The measured height values of the aggregates on the mica
surface reflect the size, i.e. thickness or diameter of the
aggregates. In Fig. 3, we present the aggregate size distribution
of the 0-h, 24-h, 72-h samples, their ThT fluorescence
intensities and representative AFM images showing the
Fig. 1 – Effects of Aβ solutions on the pSpike amplitude in urethane anesthetized rats. (A) Representative traces of pSpike
recorded after injection of 0-, 24- and 72-h Aβ solutions (1 μl, 200 μM) in the hippocampus. The 0-h Aβ solution had no effect,
whereas the 24-h solution increased and the 72-h solution decreased the amplitude of the pSpike compared to the control
(ACSF) group. (B) Time course of the effect of Aβ solutions (1 μl, 200 μM) on the pSpike (n=5 for each group) (* p<0.05). The
effects of the 24-h and 72-h solutions become statistically significant compared to the control (ACSF) group from40 min after the
end of the injection period. (C) Lack of effect of the Aβ solutions on the pEPSP of anesthetized rats.
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showed that the 0-h sample contains mostly monomers with
a height of approximately 0.5 nm (Fig. 3A). These forms of
Aβ(1–42) have high affinity to stick to the mica surface and to
each other during AFM sample preparation. After 24-h incu-
bation, small oligomers or nonspecific aggregates with a
height of approximately 1–1.5 nm and very few larger aggre-
gates with 2–3 nm size start to appear (Fig. 3A and D).
Moreover, the background of the mica surface is cleaner,
indicating a decreased number of monomers. The solution
incubated for 72 h contained a reduced number of small
oligomers and a considerable number of larger aggregates
with size of 2–4 nm (Fig. 3A and E). The abundance distribu-
tions (Fig. 3A) demonstrate that it is possible to prepare
homogenous aggregate solutions after complete monomer-
ization of the peptide samples. The observed 2–4 nm oligomersize observed after 72-h incubation is similar to that reported
in the comprehensive work of Stine et al. (2003) for oligomer
formation in PBS. This height range is also characteristic for
protofibrillar aggregates; however, in our samples, the aggre-
gates appeared to be either spherical or very short (<20–
30 nm). The presence of local maxima at ~1, ~2.4 and ~3 nm
heights in the abundance distribution plots of the 72-
h aggregates (Fig. 3A) is indicative of a non-continuous size
distribution of oligomers and the existence of unique oligomer
species. However, the exact degree of oligomerization could
not be determined by AFM, and it is important to note that
AFM measurements may underestimate the diameter of Aβ
aggregates because of sample compression by the AFM probe
(Harper et al., 1997).
The fluorescent dye, ThT has a high affinity for protein
aggregates, especially amyloid fibrils, while it does not bind to
Fig. 2 – Effects of Aβ solutions on the pSpike amplitude in freely moving rats. (A) Representative traces of pSpike recorded
before treatment and 50 min after injection of ACSF, 24- and 72-h Aβ solutions (1 μl, 200 μM) in the hippocampus for freely
moving rats. (B) Time course of the effect of Aβ solutions (1 μl, 200 μM) on the pSpike (n=5 for each group) (* p<0.05). The effects
of the 24-h and 72-h solutions become statistically significant compared to the control (ACSF) group from 30 min after the end of
the injection period. (C) Lack of effect of the Aβ solutions on the pEPSP of freely moving rats.
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the 0-h samples, suggesting that this solution containsmainly
monomeric form of the peptide (Fig. 3B). The fluorescence
intensity was found to be significantly higher in the 24-h and
72-h samples (p<0.05) (Fig. 3B), indicating the ongoing
aggregation process and increase of the amyloid-like structure
content of the solution.3. Discussion
The present study reveals that Aβ solutions with aggregates in
a different degree of oligomerization elicit opposite electro-
physiological effects on pSpike amplitude in the hippocampaldentate gyrus, which depend on the aggregation time of the
solution prior to the injection.
Inherent physiological effects have been previously dem-
onstrated only for protofibrillar and fibrillar synthetic Aβ
solutions: these included an increase in the number of
excitatory postsynaptic currents (EPSCs) and also action
potentials per minute, and an increase in the amplitude of
membrane depolarizations in primary mixed cortical cultures
(Hartley et al., 1999). Interestingly, electrophysiological effects
of protofibrils and mature fibrils were similar in that study,
while the low molecular weight Aβ, consisting solely of
monomers and/or dimers, had no significant electrophysio-
logical effect. In our study, we physico-chemically character-
ized the injected Aβ solutions in vitro, and revealed that
Fig. 3 – Characterization of the size, morphology and amyloid-like properties of Aβ aggregates. (A) Aggregate sizes in 200 μM
Aβ(1–42) solutions after 0-h, 24-h, and 72-h incubation in ACSF at room temperature. Each bar representsmeasurement from at
least 200 individual aggregates. (B) ThT fluorescence of Aβ solutions after the indicated incubation periods in ACSF. The
elevated ThT fluorescence intensity suggests an increase in the amyloid-like structure content with incubation time (* p<0.05).
(C– E) AFM images of Aβ samples after 0-h, 24-h, and 72-h incubation in ACSF, respectively. The color code on the left indicates
the height-trace range.
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incubation at room temperature contained mature fibrils.
Acute effect of in vitro-aged Aβ solutions was investigated
recently on PC12 cells. Aβ solution aged for 24 h maximally
potentiated KCl-evoked increases in Ca2+ that correlated with
oligomers composed of 3–6 monomers. Aβ solutions aged for
72 or 96 h, which generated fibrillar structures, was less
efficacious (Innocent et al., 2010).
In a recent study describing the seizure activity of APdE9
mice, the bath application of different Aβ solutions was also
examined in control rodent brain slices to confirm the
pathogenic significance of bath-applied Aβ protofibrils. Bath
application of 48-h aged Aβ solution (protofibrils) but not
oligomers (protofibrils dissolved in DMSO) induced significant
membrane depolarization of cortical layer 2/3 (L2/3) pyramidal
cells and dentate granule cells (Minkeviciene et al., 2009).
Aβ oligomerization is a continuous process which is
influenced by many factors, including concentration, molec-
ular environment, etc. (Finder and Glockshuber, 2007; Frieden,
2007; Stine et al., 2003). Moreover, it is known that in the
earliest stage of in vitro oligomerization of Aβ monomers, the
solution is dominated by small oligomers without fibrils. The
commonly accepted view is that small, diffusible oligomers
can penetrate the protein matrix of the synapse and affect
synaptic transmission, as indicated by changes in LTP (Selkoe,
2008). The Aβ solutions injected into the brain could have
different effects depending on the different oligomer sizes but
the oligomerization pattern of the injected solutions was
rarely investigated.Our AFM data revealed that in our conditions, the 24-h aged
solutions contained only small oligomers,while the appearance
of larger aggregates was only observed after 72 h incubation.
Opposite physiological effects of solutionsofhigh and low levels
of aggregation in the present study suggest different targets of
Aβ aggregates of different sizes, thoughwehave as yet no direct
evidences about the target molecules.
As far as the targets are concerned, Ye et al. (2004) have
shown, that in the Aβ induced electrical activity disclosed by
Hartley et al. (1999) activation of NMDA receptor/channels
plays a more substantial role in neuronal excitability by
protofibrils than by fibrils, whereas fibrils can have a more
selective modulation of non-NMDA receptors (Tanzi, 2005; Ye
et al., 2004), other targets cannot at present be excluded
(Verdier and Penke, 2004). Aβ aggregates of different oligomer
distribution changed only the amplitude of pSpike but failed to
change the slope of the pEPSP, indicating a rapid Aβ effect on
the spike generating ability of the cells.
Whole cell recordings in hippocampal granule cells
revealed that oligomeric Aβ decrease neuronal excitability
(Yun et al., 2006). This phenomenon had been explained by
NMDA receptor-dependent increase in dendritic excitability
(Frick et al., 2004), the selective block of the fast inactivating
potassium current (IA) (Good and Murphy, 1996). Interestingly,
differential effects of unaggregated and aggregated Aβ on K+
channel currents were also found (Ramsden et al., 2001).
A recent calcium imaging study reported hyperactive
neurons to cluster around amyloid plaques in the cortex of
APP/PS1 mice (Busche et al., 2008), which points to the
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homeostasis in AD (Hermes et al., 2010; Small, 2009; Yu et al.,
2009). The thoroughly investigated increase in cytoplasmic Ca2+
by Aβ is principally due to an influx of extracellular Ca2+ across
the cell membrane, although the mechanism by which Ca2+
influx is stimulated by Aβ remains obscure (Small, 2009).
Several mechanisms have been proposed for the Ca2+
influx; impaired membrane ATPase activity, lipid peroxida-
tion, artificial membrane pores or that Aβ can trigger Ca2+
influx through endogenous membrane ion channels (Small,
2009). Disruption of neuronal membrane integrity by 48-
h aged Aβ and the disturbance of voltage-dependent channel
functions yields robust changes to resting membrane poten-
tial that could underscore sustained membrane depolariza-
tion of cortical L2/3 pyramidal cells and dentate granule cells
(Minkeviciene et al., 2009).
On the neuronal population level, one may assume that
these changes could also affect other than pyramidal cells, i.e.
the inhibitory interneurons, thus could compensate for
changes in an enhanced excitatory tone in cortical neuronal
networks. This question was addressed by recording extra-
cellular field potentials in L2/3 pyramidal cells while stimu-
lating afferent fibers in L1 before and after acute bath
application of 48-h aged Aβ, and similarly to our 24-h Aβ
results it significantly increased the neuronal population
activity (Minkeviciene et al., 2009).
In conclusion, different oligomers, chemically character-
ized to be in a different oligomerization state, when injected in
vivo elicited different electrophysiological actions on the
neuronal population activity. The exact mechanism of how
the different Aβ oligomers influence neuronal excitability,
whether it is a consequence of an interaction with a specific
ion channel, ion transporter or a nonspecific effect on
neuronal plasma membranes, remains the subject of further
research.4. Experimental procedures
4.1. Electrophysiological experiments
The care and treatment of all animals conformed to Council
Directive 86/609/EEC, the Hungarian Act of Animal Care and
Experimentation (1998, XXVIII), and local regulations for the
care and use of animals in research. All efforts were taken to
minimize the animals’ pain and suffering and to reduce the
number of animals used.
Acute experiments were conducted on male Sprague-
Dawley rats (n=20) weighing ~250 g (n=5 per group) from
Charles River Laboratories Hungary, which were anesthetized
by intra-peritoneal urethane (Sigma-Aldrich Co., Budapest,
Hungary) (1 g/kg) administration and positioned in a stereo-
taxic frame. Body temperature was maintained by a heating
pad and a temperature controller unit (TMP-5b, SuperTech Inc,
Pécs, Hungary).
Field potentials were evoked by stimulating the perforant
pathway (AP:-8.3 L:4.8 V:3.4) (Andersen et al., 1971); Paxinos
andWatson, 1986) with a bipolar stimulating electrode (bifilar
stainless steel 316LVM, California Fine Wire, CA, USA).
Recording electrodes were implanted into the hilus of thedentate gyrus of the ventral hippocampus (AP:-4.8 L:4.5 V:4.5)
(Paxinos andWatson, 1986). The distance between the tips of
the two wires within the bipolar electrode was 0.6–0.8 mm.
During the surgical procedure, electrodes were advanced
slowly downward until reaching the optimal depth to record
pSpike. To record during implantation and experiment a
Neurofax EEG amplifier (Nihon Kohden, Tokyo, Japan, time
constant: 5.0 s, band pass 0.2–3000 Hz, sensitivity: 300 μV/
mm) was used. Using a BioStim (SuperTech Inc, Pécs,
Hungary) digitally controlled stimulator, square-wave pulses
of 0.1 ms duration were applied, 1 per minute. Stimulus
intensity was set to evoke 50% of the maximum amplitude of
the pSpike. After the optimal depth to record pSpike had been
reached, control data were acquired after a 30 min delay to
allow the tissue to recover from any trauma due to the
electrode implantation, using the same recording and stim-
ulation procedure as under implantation.
A fused silica capillary (Fused Silica Capillary TSP075150,
Optronis GmbH, Kehl, Germany) was used to inject Aβ
solutions. The capillary was glued to the bipolar recording
electrode at the level of the upper tip. Solutions of either 1 μl of
200 μM Aβ (total amount of Aβ injected was 0.2 nmol per
animal) or vehicle were injected using a micro-perfusion
pump (KD-Scientific 1001i, KD-Scientific Inc., Holliston, MA,
USA) at a flow rate of 0.03 μl/min. In the case of the 0-h
incubation solution it took about 5 min to prepare the Aβ
solution for injections and about 30 min to inject the 1 μl
solution into the brain. This way the average period of
incubation for the 0-h sample before entering the brain tissue
was 20 min.
Recording of pSpikewas performed using the same settings
as during implantation (see above). Responses were digitized
by a CED 1401micro analogue-digital converter (Cambridge
Electronic Design Ltd., Cambridge, UK), stored on a computer
and averaged offline using Signal 1.9 software. Sampling rate
was set to 10 kHz. Thirty responses were recorded as baseline
for each experiment. The average of these sweeps served as
the control pSpike and population excitatory postsynaptic
potential (pEPSP) and their amplitude and slope were
expressed as percentage of these control values. Evaluation
of the recorded data was conducted using AxoGraph 1.1,
Origin 7.0 and Statistica for Win 7.1.
Since urethane anesthesia affects the characteristics of
hippocampal evoked potentials (Riedel et al., 1994) the
effective aggregates were also tested in awake rats. These
experiments were conducted on male Sprague-Dawley rats
(n=15) weighing ~250 g (n=5 per group) (Charles River
Laboratories Hungary, Budapest, Hungary), which were anes-
thetized with halothane (Narcotane, Lecive, Prague, Czech
Republic) (0.6% in air) for electrode implantation and received
pain killers and antibiotics after surgery.
Experimental conditions (location of electrodes, stimula-
tion and recording parameters) were the same as in the acute
recordings. After a week of recovery from surgery, pSpike
were recorded using the same stimulating and recording
conditions asunder implantation. The stimulus intensitywas
set to evoke half of the maximum amplitude of pSpike.
During implantation, a guide cannula (0.4 mm outer diame-
ter) was attached to the recording electrode 0.5 mmabove the
tip of the electrodes. A silica capillary was inserted into the
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the Aβ solutions. The type of capillary tube, flow rate,
concentration and injection volume were the same as in the
acute experiments.
After all electrophysiological experiments, the location of
the electrode tips was histologically verified with Gallyas
silver staining (Gallyas et al., 1993).
4.2. Preparation of amyloid β solutions for
in vivo experiments
Amyloid-β peptide (Aβ(1–42)) was produced by solid carrier
synthesis as described by Zarandi et al. (2007). The peptide
was dissolved in 100% hexafluoro-isopropanol (HFIP) for 6 h
to disaggregate Aβ and prepare monomer solution. The
solution was then centrifuged in an Eppendorf tube for
10 min; the supernatant was frozen in liquid nitrogen,
lyophilized, and kept at −80 °C until use. To prepare different
aggregates in vitro in a solution suitable for in vivo experi-
ments, lyophilized sampleswere dissolved at a concentration
of 200 μM inACSF and incubated at room temperature for 0, 24
or 72 h prior to administration.
4.3. In vitro characterization of Aβ(1–42) aggregate size
and morphology
The morphology, size and amyloid-like properties of Aβ
aggregates, formed in ACSF after 0, 24 and 72 h incubation,
were characterized by atomic force microscopy (AFM), and
thioflavin-T fluorescence (ThT, Sigma-Aldrich Co., Budapest,
Hungary). In the case of the 0-h sample a preincubation of
20 min was applied to fit to the average preincubation time of
the solution in in vivo experiments. AFM measurements were
carried out either on dry samples or in liquid. For dry samples
(0 h), Aβ solutions were diluted 10-fold in water, incubated on
mica surface for 10 min, rinsed with water and dried up in air.
For measurements in liquid (0, 24 and 72 h samples), Aβ
solution were diluted 500- to 1000-fold in water, incubated on
mica for 2 min and then replaced with deionized water by
repeated addition and removal. Non-contact mode images
were acquired with an MFP3D AFM instrument (Asylum
Research, Santa Barbara, CA), using silicon nitride cantilevers
(Olympus AC160 and Olympus BioLever for dried and wet
samples, respectively, Oympus, Tokyo, Japan). The drive
amplitude and contact force were kept to a minimum. Sample
areas (1–5 μm wide) were scanned at 0.5–1 Hz rate into
512×512 images. The images were evaluated for height traces
by measuring the height of at least 200 individual aggregates
above the mica surface using the MFP-3D software (Asylum
Reserach, Santa Barbara, CA). Larger objects, that could be
seen as clearly associated from several aggregates were
probable artifacts of AFM sample preparation, were not
included in the analysis.
For ThT fluorescence measurements, 3 μl aliquots were
taken from the samples and mixed with 1.0 ml of 5 μM ThT in
50 mM glycine, 100 mM NaCl (pH: 8.5) (Naiki and Gejyo, 1999).
Fluorescence intensity of ThT was monitored at 485 nm with
excitation at 445 nm at 25 °C, using a Fluoromax (SPEX
Industries, Edison, NJ, USA). Excitation and emission band-
widths were set to 5 and 10 nm, respectively.4.4. Statistical analysis of the results
Experimental animal groups were statistically compared with
one-way ANOVA using Tukey means comparison post-hoc
test at each timepoint. Before conducting this analysis
Kolmogorov–Smirnov normality test was run on the whole
set of results to test the normal distribution of values.
In order to determine from which timepoint is the effect of
the treatment significant within an experimental group, the
mean amplitude value of the pre-treatment baseline of each
group was compared to the mean of the sample at each
timepoint using one-sample Student's t-test.
Note, that the amplitude of the pSpike increased in control
(ACSF) group during the experiments too. This suggests that
the pSpike amplitude was influenced by a factor independent
of the quality of the injected compound. Statistical test
comparing the post-treatment mean values at each timepoint
separately to the mean value of the baseline period revealed
that this effect was significant from 30 min after the start of
the treatment. Therefore all results were normalized to the
values measured in control (ACSF) groups at the same
timepoint to eliminate this factor. This phenomena supported
the importance of repeating the experiments on freelymoving
animals to avoid the possible influence of the anesthesia on
our results.
In order to reliably estimate the onset of the effects of the
different treatments, the statistical comparison of the mean
amplitude values at each timepoint to the mean amplitude
value of the baseline was conducted using the corrected
parameters. The 24-h solutions effect reached significant level
at the end of the 30 min infusion. The 72-h solution signifi-
cantly decreased the pSpike amplitude 20 min after the end of
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